Previous Close | 0.1550 |
Open | 0.1550 |
Bid | 0.1500 x 0 |
Ask | 0.1550 x 0 |
Day's Range | 0.1500 - 0.1600 |
52 Week Range | 0.0700 - 0.1800 |
Volume | 1,381,880 |
Avg. Volume | 1,548,593 |
Market Cap | 114.365M |
Beta (5Y Monthly) | 1.79 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0180 |
Earnings Date | Apr 16, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Cannara's three new brands – Tribal, Nugz and Orchid CBDMONTREAL, Feb. 25, 2021 /CNW/ - Cannara Biotech Inc.
\- Expects to generate revenue from letter of intent with the Société québécoise du cannabis by end of February or early March 2021 -MONTREAL, Jan. 29, 2021 /CNW/ - Cannara Biotech Inc.
Cannara Biotech Inc.("Cannara" or the "Company") (CSE: LOVE) (OTCQB: LOVFF) (FRA: 8CB) is pleased to announce that, through its wholly-owned subsidiary, Cannara Biotech (Quebec) Inc., it has received approval from Health Canada to amend its license to permit the sale of dried cannabis products to provincially authorized distributors and retailers nationwide. As revenue steadily grows over the next 12 months, Cannara expects rapid growth in profitability and cashflow given its lean operating structure and production cost advantage.